Orthofix International (OFIX) Tops Q4 EPS by 5c; Guides FY12 EPS Below Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St set to open lower as oil jump, high yields fuel inflation concerns
- Oil jumps as Middle East supply concerns persist amid shipping attacks
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Lynx sees AI semiconductor rally extending into year-end
Tweet
Share
E-mailGet Alerts OFIX Hot Sheet
Price: $9.20 --0%
Revenue Growth %: +3.6%
Financial Fact:
Operating income (loss): 9.27M
Today's EPS Names:
PKE, BYRN, HELE, More
Revenue Growth %: +3.6%
Financial Fact:
Operating income (loss): 9.27M
Today's EPS Names:
PKE, BYRN, HELE, More
Join SI Premium – FREE
Orthofix International (NASDAQ: OFIX) reported Q4 EPS of $0.80, $0.05 better than the analyst estimate of $0.75. Revenue for the quarter came in at $151.5 million versus the consensus estimate of $150.97 million.
Orthofix International sees FY2012 EPS of $2.95-$3.05, versus the consensus of $3.07. Orthofix International sees FY2012 revenue of $595-$605 million, versus the consensus of $606.70 million.
For earnings history and earnings-related data on Orthofix International (OFIX) click here.
Orthofix International sees FY2012 EPS of $2.95-$3.05, versus the consensus of $3.07. Orthofix International sees FY2012 revenue of $595-$605 million, versus the consensus of $606.70 million.
For earnings history and earnings-related data on Orthofix International (OFIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novagold Resources, Inc. (NG) Misses Q3 EPS by 2c
- Byrna Technologies Inc. (BYRN) Misses Q3 EPS by 9c
- Biofrontera files sNDA to expand Ameluz use to full-body skin lesions
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
